Two recent trials have impacted the way many ep's are starting to look at anticoagulation, especially for those with short duration episodes and a low afib burden.
This is by no means a green light to stop taking anticoagulants on your own, but it suggests a conversation with your doctor might be in order for some of us.
Excerpts below on Dr. John Mandrola's commentary on these two studies.
"For an older patient with stroke risk factors and 3 hours of AF on a cardiac device, pre-2023 thinking would have us leaning toward anticoagulation. The results of the ARTESIA and NOAH-AFNET 6 trials strongly question that idea.
NOAH-AFNET randomly assigned about 2500 older patients with short-duration device-detected AF (median duration, 2.8 hours) to edoxaban vs placebo. The trial was stopped early at 21 months for perceived futility and excess bleeding in the edoxaban arm. Edoxaban reduced the primary endpoint of stroke, systemic embolism, and cardiovascular death by 19% (HR, 0.81; 95% CI, 0.60-1.08; P = .15) but increased bleeding by 31% (HR, 1.31; 95% CI, 1.02-1.67; P = .03).
ARTESIA randomly assigned about 4000 older patients with short-duration AF (median duration, 1.5 hours) to apixaban vs aspirin. More patients and longer follow-up of 3.5 years translated to more events. Apixaban reduced the primary endpoint of stroke or systemic embolism by 37% (HR, 0.63; 95% CI, 0.45- 0.88; P = .007). This was countered by an 80% increase in major bleeding (HR, 1.80; 95% CI, 1.26- 2.57; P = .001).
The results of both trials were consistent: Direct-acting oral anticoagulants reduce thrombotic events but increase bleeding rates. The biggest discovery — and reason for debate about net benefit — was the low stroke rates (< 1% per patient-year) in both trials. What clinicians need, and is probably forthcoming, is an analysis correlating duration of AF and net benefit. Right now, anticoagulation decisions with device-detected short-duration AF require high doses of judgement and patient preference."
Jim